EM1 ann -- Wholly-owned subsidiary Mernova Medicinal Inc....

EM1 ann -- Wholly-owned subsidiary Mernova Medicinal Inc. confirmed POs for October delivery anticipate highest ever monthly revenue following record growth in Q3 FY23
Highlights:
• A$891,9441 in unaudited revenue expected to be delivered in October 2023 based on sales to date
and confirmed purchase orders received – highest ever sales month for Mernova since inception
• Considerably exceeds previous record month of February 2022 (A$808,817) with potential to grow
further as additional purchase orders are delivered

STK moving upwards today imo
Heritage: the Heritage survey was successfully completed last week, with the Company awaiting the final report
Aircore drilling: the ongoing 50,000m aircore drill program is continuing as planned, with the rig having returned
to undertaking systematic fence lines across the Horse Well area. A number of promising areas are expected to be drilled over the coming week
Additional rigs: an RC rig is scheduled to arrive next week, and a diamond rig will arrive the following week. The
focus of the additional rigs will be to drill Marwari, Great Western, Rabbit Well, Chetak and follow up any additional
anomalism at Konik or new discoveries on the Pegasus trend.